Immunotherapy With Adaptive Pulse Radiotherapy in Solid Tumors
Recruiting
Phase 2
Interventional Study
Cancer
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 19 and older
- Sex
- Any
- Trial phase
- Phase 2
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 35 (estimated)
- Sponsor
- Samsung Medical Center · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The goal of this clinical trial is to find out whether Adaptive Pulse Radiotherapy (Pulse RT) combined with immune checkpoint inhibitors (ICIs) helps treat advanced solid tumors.
It will also check how safe this combined treatment is and how it affects the immune system and quality of life.
The main questions the study will try to answer are:
Does adding Pulse RT to ICIs improve tumor response …
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Eastern Cooperative Oncology Group (ECOG) performance status 0-2
* Histologically confirmed solid tumor (radiologic diagnosis allowed for hepatocellular carcinoma)
* Currently receiving or planned to receive immune checkpoint inhibitor (ICI) therapy
* Presence of at least one …
Contacts